Disruption of growth hormone signaling retards prostate carcinogenesis in the probasin/Tag rat

Endocrinology

Volumn 149, Issue 3, 2008, Pages 1366-1376

  Wang, Zhuohua ^a   Luque, Raul M ^a   Kineman, Rhonda D ^a   Ray, Vera H ^c   Christov, Konstantin T ^a   Lantvit, Daniel D ^a   Shirai, Tomoyuki ^d   Hedayat, Samad ^a   Unterman, Terry G ^a,b   Bosland, Maarten C ^a   Prins, Gail S ^a   Swanson, Steven M ^a,e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c Jr Hospital of Cook County   (United States)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^e Department of Medicinal Chemistry and Pharmacognosy ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; PROBASIN; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; TESTOSTERONE;

ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER RESISTANCE; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; GENE MUTATION; INVASIVE CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

ADENOCARCINOMA; ANDROGEN-BINDING PROTEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS, VIRAL, TUMOR; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GROWTH HORMONE; INSULIN-LIKE GROWTH FACTOR I; MALE; MUTATION; PROSTATE; PROSTATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, IGF TYPE 1; RECEPTORS, ANDROGEN; RECEPTORS, SOMATOTROPIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; TESTOSTERONE;

EID: 40849111657     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-1410     Document Type: Article

References (56)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ 2007 Cancer statistics, 2007. CA Cancer J Clin 57:43-66
2. Colao A, Di Somma C, Spiezia S, Filippella M, Pivonello R, Lombardi G 2003 Effect of growth hormone (GH) and/or testosterone replacement on the prostate in GH-deficient adult patients. J Clin Endocrinol Metab 88:88-94
3. Colao A, Spiezia S, Di Somma C, Marzullo P, Cerbone G, Pivonello R, Faggiano A, Lombardi G 2000 Effect of GH and/or testosterone deficiency on the prostate: an ultrasonographic and endocrine study in GH-deficient adult patients. Eur J Endocrinol 143:61-69
4. Colao A, Marzullo P, Spiezia S, Giaccio A, Ferone D, Cerbone G, Di Sarno A, Lombardi G 2000 Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. J Clin Endocrinol Metab 85:3754-3761
5. Reiter E, Kecha O, Hennuy B, Lardinois S, Klug M, Bruyninx M, Closset J, Hennen G 1995 Growth hormone directly affects the function of the different lobes of the rat prostate. Endocrinology 136:3338-3345
6. Pollak M, Beamer W, Zhang JC 1998 Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 17:383-390
7. Butler AA, LeRoith D 2001 Minireview: tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology. Endocrinology 142:1685-1688
8. Roberts Jr CT 2004 IGF-1 and prostate cancer. Novartis Found Symp 262: 193-199; discussion 199-204, 265-198
9. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563-566
10. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB 2000 Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 85:4258-4265
11. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R 2000 Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92:1910-1917
12. Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D 2003 Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 63:3991-3994
13. Oliver SE, Gunnell D, Donovan J, Peters TJ, Persad R, Gillatt D, Pearce A, Neal DE, Hamdy FC, Holly J 2004 Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. Int J Cancer 108:887-892
14. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO 1997 Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76:1115-1118
15. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D 1998 Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90:911-915
16. Wolk A, Andersson SO, Mantzoros CS, Trichopoulos D, Adami HO 2000 Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening? Lancet 356:1902-1903
17. Khosravi J, Diamandi A, Mistry J, Scorilas A 2001 Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J Clin Endocrinol Metab 86:694-699
18. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E 2002 Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94:1099-1106
19. Li L, Yu H, Schumacher F, Casey G, Witte JS 2003 Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 14:721-726
20. Cutting CW, Hunt C, Nisbet JA, Bland JM, Dalgleish AG, Kirby RS 1999 Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int 83:996-999
21. Janssen JA, Wildhagen MF, Ito K, Blijenberg BG, Van Schaik RH, Roobol MJ, Pols HA, Lamberts SW, Schroder FH 2004 Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. J Clin Endocrinol Metab 89:4391-4396
22. Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS 2005 Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 103:76-84
23. Kurek R, Tunn UW, Eckart O, Aumuller G, Wong J, Renneberg H 2000 The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer. BJU Int 85:125-129
24. Finne P, Auvinen A, Koistinen H, Zhang WM, Maattanen L, Rannikko S, Tammela T, Seppala M, Hakama M, Stenman UH 2000 Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 85:2744-2747
25. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M 2004 Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346-1353
26. Shi R, Berkel HJ, Yu H 2001 Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 85:991-996
27. Fuhrman B, Barba M, Schunemann HJ, Hurd T, Quattrin T, Cartagena R, Carruba G, Muti P 2005 Basal growth hormone concentrations in blood and the risk for prostate cancer: a case-control study. Prostate 64:109-115
28. Wang Z, Prins GS, Coschigano KT, Kopchick JJ, Green JE, Ray VH, Hedayat S, Christov KT, Unterman TG, Swanson SM 2005 Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. Endocrinology 146:5188-5196
29. Asamoto M, Hokaiwado N, Cho YM, Takahashi S, Ikeda Y, Imaida K, Shirai T 2001 Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. Cancer Res 61:4693-4700
30. Okuma S 1984 [Study of growth hormone in spontaneous dwarf rat]. Nippon Naibunpi Gakkai Zasshi 60:1005-1014 (Japanese)
31. Takeuchi T, Suzuki H, Sakurai S, Nogami H, Okuma S, Ishikawa H 1990 Molecular mechanism of growth hormone (GH) deficiency in the spontaneous dwarf rat: detection of abnormal splicing of GH messenger ribonucleic acid by the polymerase chain reaction. Endocrinology 126:31-38
32. Nogami H, Takeuchi T, Suzuki K, Okuma S, Ishikawa H 1989 Studies on prolactin and growth hormone gene expression in the pituitary gland of spontaneous dwarf rats. Endocrinology 125:964-970
33. Okuma S 1980 Spontaneous dwarf rat. Exp Anim 29:301-305
34. Gargosky SE, Nanto-Salonen K, Tapanainen P, Rosenfeld RG 1993 Pregnancy in growth hormone-deficient rats: assessment of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs) and IGFBP protease activity. J Endocrinol 136:479-489
35. Nogami H, Watanabe T, Takeuchi T 1992 Effect of growth hormone (GH) on the promotion of body weight gain in the spontaneous dwarf rat: a novel experimental model for isolated GH deficiency. Horm Metab Res 24:300-301
36. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD 2004 Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64:2270-2305
37. Bostwick DG 1995 High grade prostatic intraepithelial neoplasia. Cancer 75(S7):1823-1836
38. Luque RM, Gahete MD, Hochgeschwender U, Kineman RD 2006 Evidence that endogenous SST inhibits ACTH and ghrelin expression by independent pathways. Am J Physiol Endocrinol Metab 291:E395-E403
39. Luque RM, Kineman RD 2006 Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. Endocrinology 147:2754-2763
40. Heyns W, De Moor P 1977 Prostatic binding protein. Asteroid-binding protein secreted by rat prostate. Eur J Biochem 78:221-230
41. Colao A, Marzullo P, Spiezia S, Ferone D, Giaccio A, Cerbone G, Pivonello R, Di Somma C, Lombardi G 1999 Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. J Clin Endocrinol Metab 84:1986-1991
42. Colao A, Marzullo P, Ferone D, Spiezia S, Cerbone G, Marino V, Di Sarno A, Merola B, Lombardi G 1998 Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab 83:775-779
43. Dodd JG, Sheppard PC, Matusik RJ 1983 Characterization and cloning of rat dorsal prostate mRNAs. Androgen regulation of two closely related abundant mRNAs. J Biol Chem 258:10731-10737
44. Matusik RJ, Kreis C, McNicol P, Sweetland R, Mullin C, Fleming WH, Dodd JG 1986 Regulation of prostatic genes: role of androgens and zinc in gene expression. Biochem Cell Biol 64:601-607
45. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M 2000 p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769-1775
46. Hsieh JT, Zhau HE, Wang XH, Liew CC, Chung LW 1992 Regulation of basal and luminal cell-specific cytokeratin expression in rat accessory sex organs. Evidence for a new class of androgen-repressed genes and insight into their pairwise control. J Biol Chem 267:2303-2310
47. Prins GS, Birch L 1995 The developmental pattern of androgen receptor expression in rat prostate lobes is altered after neonatal exposure to estrogen. Endocrinology 136:1303-1314
48. Cunha GR, Young P 1991 Inability of Tfm (testicular feminization) epithelial cells to express androgen-dependent seminal vesicle secretory proteins in chimeric tissue recombinants. Endocrinology 128:3293-3298
49. Iwamura M, Sluss PM, Casamento JB, Cockett AT 1993 Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 22:243-252
50. Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS, Plymate SR 1996 Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 81:3774-3782
51. Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M, Mosberger I, Upton MP, Bubley GJ, Balk SP 1999 Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 155:1271-1279
52. Plymate SR, Bae VL, Maddison L, Quinn LS, Ware JL 1997 Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. Endocrinology 138:1728-1735
53. Bostwick DG, Eble JN 1997 Urologic surgical pathology. 1st ed. St. Louis: Mosby
54. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ 2002 Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623-646
55. van der Lely AJ, Kopchick JJ 2006 Growth hormone receptor antagonists. Neuroendocrinology 83:264-268
56. Schally AV, Varga JL 2006 Antagonists of growth hormone-releasing hormone in oncology. Comb Chem High Throughput Screen 9:163-170